会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • METHODS OF DIAGNOSING AND TREATING AUTOIMMUNE DISEASE
    • 诊断和治疗自发性疾病的方法
    • WO2016164402A1
    • 2016-10-13
    • PCT/US2016/026129
    • 2016-04-06
    • OKLAHOMA MEDICAL RESEARCH FOUNDATION
    • GAFFNEY, PatrickJAMES, Judith
    • A61K35/74A61K45/06C12N1/20
    • A61K45/06A61K31/7048C12Q1/6883C12Q1/689G01N33/564G01N33/56911G01N2800/104
    • The present disclosure relates to methods of diagnosing and treating Systemic Lupus Erythematosus (SLE) based on microbe population alterations in the oral cavity and intestines. It has been discovered that SLE patients present with the following abnormalities as compared to healthy individuals: (1) decreases in the general microbial diversity in fecal samples; (2) decreases in the microbial phyla Bacteroidetes in fecal samples; (3) decreases in the Faecalibacterium genus in fecal samples; (4) decreased phylogenetic and species diversity in saliva samples; (5) increases in the microbial phyla Bacteroidetes in saliva samples; and (6) increased levels of the Prevotella genus in saliva. Thus, the present disclosure provides methods of diagnosing SLE by exploiting these abnormalities. Furthermore, the present disclosure provides methods of treating SLE by resolving the above microbe abnormalities.
    • 本公开涉及基于口腔和肠道中的微生物群体改变来诊断和治疗系统性红斑狼疮(SLE)的方法。 已经发现与健康个体相比,SLE患者具有以下异常:(1)粪便样品中一般微生物多样性降低; (2)粪便样本中微生物菌类菌的数量减少; (3)粪便样本中粪便杆菌属数量减少; (4)减少唾液样品的系统发育和物种多样性; (5)唾液样本中微生物菌类菌的数量增加; 和(6)唾液中Prevupella属的水平提高。 因此,本公开提供了通过利用这些异常来诊断SLE的方法。 此外,本公开提供了通过解决上述微生物异常来治疗SLE的方法。
    • 4. 发明申请
    • DISPERSION INJECTION METHODS FOR BIOSENSING APPLICATIONS
    • 生物传感应用的分散注射方法
    • WO2012087840A1
    • 2012-06-28
    • PCT/US2011/065613
    • 2011-12-16
    • FLIR SYSTEMS, INC.QUINN, John, Gerard
    • QUINN, John, Gerard
    • G01N21/05
    • G01N33/53G01N21/05G01N21/272G01N21/45G01N21/553G01N21/7703G01N35/00693G01N35/08
    • I Injection methods for determining biomolecular interaction parameters such in label-free biosensing systems are provided. The methods generally relate to analyte sample injection methods that generate well-defined analyte concentration gradients en route to a sensing region possessing an immobilized binding partner. The injections conditions are generally established according to a set of rules that create a dispersion event that can be accurately modeled by a dispersion term. The dispersion term is incorporated into the desired interaction model to provide a reliable representation of the analyte concentration gradient profile, The resulting interaction model is then fitted to a measured binding response curve in order to calculate the interaction parameters. Thus, the injection methods described herein provide a continuous analyte titration allowing a full analyte dose response to be recorded in a single injection in contrast to the standard multiple injection approach
    • 提供了用于确定生物分子相互作用参数的注射方法,例如无标记的生物传感系统。 所述方法通常涉及分析物样品注射方法,其在通向具有固定化结合配偶体的感测区域途中产生明确定义的分析物浓度梯度。 注射条件通常根据创建可以通过色散项精确建模的色散事件的一组规则建立。 将分散项合并到所需的相互作用模型中以提供分析物浓度梯度分布的可靠表示。然后将所得的相互作用模型拟合到测量的结合响应曲线上,以计算相互作用参数。 因此,本文所述的注射方法提供连续的分析物滴定,与标准多次注射方法相反,允许在单次注射中记录完整的分析物剂量反应